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Stroke is a rare disease in childhood with an estimated incidence of 1-6/100.000. It has an increasingly recognised
impact on child mortality along with its outcomes and effects on quality of life of patients and their families.
Clinical presentation and risk factors of paediatric stroke are different to those of adults therefore it can be
considered as an indipendent nosological entity. The relative rarity, the age-related peculiarities and the variety of
manifested symptoms makes the diagnosis of paediatric stroke extremely difficult and often delayed. History and
clinical examination should investigate underlying diseases or predisposing factors and should take into account
the potential territoriality of neurological deficits and the spectrum of differential diagnosis of acute neurological
accidents in childhood. Neuroimaging (in particular diffusion weighted magnetic resonance) is the keystone for
diagnosis of paediatric stroke and other investigations might be considered according to the clinical condition.
Despite substantial advances in paediatric stroke research and clinical care, many unanswered questions remain
concerning both its acute treatment and its secondary prevention and rehabilitation so that treatment
recommendations are mainly extrapolated from studies on adult population. We have tried to summarize the
pathophysiological and clinical characteristics of arterial ischemic stroke in children and the most recent
international guidelines and practical directions on how to recognise and manage it in paediatric emergency.
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Stroke is defined as a sudden loss of brain function
caused by a decreased cerebral blood flow. It can occur
at all life stages but clinical presentation, pathophysi-
ology and other clinical perspectives are variable de-
pending on the patient’s age.
While many efforts and important clinical trials have
been allocated to increase knowledge about adult stroke,
paediatric stroke often remains an under-recognized
nosological entity even among paediatricians, although it
is an important cause of lifelong disability with a human* Correspondence: luigi.titomanlio@rdb.aphp.fr
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The estimated incidence of paediatric stroke is 1–6 per
100,000 children per year [4–6].
Rates of perinatal stroke (until 28 days after birth) are
even higher, occurring in at least 1 in 3,500 live-births.
Perinatal stroke differs from paediatric stroke in some
clinical and pathophysiological aspects, mainly overlap-
ping with global hypoxic ischemic encephalopathy and
presenting with more aspecific and generalised signs
such as apnea, hypotonia, poor feeding, seizures and ir-
ritability [7–11].
Differently, in children focal neurological deficits such
as hemiplegia are the most frequently reported signs and
the most frequently affected artery is middle cerebral ar-
tery (MCA).
In this review we have tried to focus on risk factors
and underlying mechanisms, diagnosis, treatment,distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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needs about paediatric arterial ischemic stroke (AIS).
Risk factors for paediatric stroke
Presumptive risk factors for paediatric stroke differ in chil-
dren compared with adults. Whereas adult risk factors are
primarily related to arrhythmias, obstructive atheroscler-
otic arteriopathies and socioeconomic status, these are
rarely found to be related to stroke in children [12, 13].
In several studies, such as the International Paediatric
Stroke Study (IPSS), a wide range of underlying systemic
factors were reported in the setting of childhood stroke,
in particular: sickle cell disease (SCD), cardiac disorders,
trauma, and major infections such as meningitis, sepsis
and encephalitis. However, in the majority of the chil-
dren, no underlying systemic disease was found [14].
Arteriopathy
With the advances in neuroimaging, arteriopathy appears
to be the predominant underlying mechanism, causing
53 % of paediatric strokes. Furthermore, it represents the
greatest predictor of recurrence, emphasising its role as a
treatment target for secondary stroke prevention [13, 15].
The most common established arteriopathy in paediat-
ric stroke is an acquired unilateral intracranial arteriopa-
thy associated with basal ganglia stroke, characteristically
involving the junction of the distal internal carotid artery,
the proximal MCA and the proximal anterior cerebral ar-
tery (ACA). This condition was originally designed as a
transient cerebral arteriopathy (TCA) and characterised
by its time course, by an unilateral location, and by the
absence of a long-term progression [16, 17]. On initial
traditional imaging, TCA may be not distinguishable from
a progressive arteriopathy such as Moyamoya disease
(MMD) or from a vasculitis that presents unilaterally, with
a different course and prognosis. Few clinical and
radiological parameters may help predict the course of
childhood unilateral intracranial arteriopathy. It has been
described that patients with progressive arteriopathy more
often show arterial occlusion, ACA involvement and
abnormal collateral vessels and that a mainly cortical
localization is associated with poor functional out-
come. The distinction between TCA and progressive
arteriopathy may require further radiological assessment,
such as magnetic resonance angiography (MRA) and con-
ventional angiography, and, in general, its worsening after
6 months or a bilateral involvement suggests an arteriopa-
thy other than TCA [16, 18].
Conscious of the limitations in classifying arteriopathies
on initial imaging, the IPSS has recently suggested the
term “focal cerebral arteriopathy” of childhood (FCA) to
describe children with an unilateral arterial stenosis
without an apparent underlying cause at presentation.
These arteriopathies are clinically important because theirpresence indicates an increased risk for recurrent stroke
and vascular imaging of intracranial and neck vessels are
imperative to detect them.
The underlying mechanisms for these unilateral,
monophasic arteriopathies are poorly understood. Inves-
tigators originally proposed that the basis for this dis-
order was inflammatory, but currently the possible role
of infection is the most plausible hypothesis. In particu-
lar, chickenpox is associated to AIS with an absolute risk
of 1 in 15,000 children and varicella-associated AIS in-
cludes nearly one third of childhood AIS. It has been re-
ported that in young children with AIS there is a 3-fold
increase in preceding varicella infection compared with
population rates and this prevalence was higher than the
annual prevalence of chickenpox reported in the re-
gional population [19]. The fact that post-varicella
angiopathy, consisting in a non-progressive arteriopathy,
has similar arterial imaging but a presumed infectious
cause suggests that TCA might sometimes have a link to
infectious mechanisms [17]. Furthermore, acute infec-
tion has been shown to be a risk factor and a potential
trigger for spontaneous cervical artery dissection and
upper respiratory infections (URI) have recently been re-
lated to transient arteriopathy. In the IPSS, a recent URI
was noted in 9.1 % of children with a cerebral arteriopa-
thy and based on the preliminary results of the Vascular
Effects of Infection in Pediatric Stroke (VIPS) study, in-
fections ≤1 week prior to stroke/interview date con-
ferred a 6.5-fold risk of AIS and the most common type
of infection described was upper respiratory. Also, chil-
dren reported to have had some/few/no routine vaccina-
tions were at higher risk of AIS than those receiving all
or most, suggesting that a higher frequency of upper re-
spiratory diseases may increase the incidence of pediatric
AIS and that their prevention might prevent stroke in
pediatric patients [20–23]. In conclusion, although many
underlying diseases have been reported in the setting of
childhood AIS, emerging research demonstrates that
non-atherosclerotic intracerebral arteriopathies in other-
wise healthy children are prevalent. In particular, these
conditions are related to parainfectious aetiology, inflam-
matory reaction and altered inflammation signalling [13].
Genetical factors and Moyamoya syndrome
Genetically determined arteriopathies are increasingly
recognised as a cause of childhood AIS. The list con-
tinues to expand, including COL4A1, ACTA2, and peri-
centrin (MOPD2) mutations, and syndromes such as
Alagille’s and PHACE.
The most studied syndrome is the Moyamoya disease
which accounts for 6 % of childhood AIS. It is character-
ized by a usually bilateral progressive stenosis or occlu-
sion of the intra-cranial internal carotid apices, involving
the anterior and medial cerebral arteries. MMD is
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of Japanese patients and other mutations of BRCC3/
MTCP1 and GUCY1A3 have recently been reported in
more complex Moyamoya syndromes [24].
In 2014, a genetic arteriopathy caused by a deficiency
of adenosine deaminase 2 (ADA2) was reported with
clinical features that included intermittent fever, lacunar
strokes beginning in early childhood and livedoid rash;
histopathological changes included compromised endo-
thelial integrity, endothelial cellular activation and in-
flammation [16, 25].
Hereditary coagulopathies and trombophilia
One or more prothrombotic states have been identified
in 20 to 50 % of children presenting with AIS [26]. The
main mutations associated with prothrombotic states are
described in factor V Leiden, prothrombin G20210A,
methylenetetrahydrofolate reductase (MTHFR; C677 T
and A1298 C), protein C, protein S, antithrombin and
lipoprotein (a) [27–29]. Most paediatric stroke experts be-
lieve that coagulopathy represents a potential risk factor
for stroke usually working in combination with other fac-
tors, rather than being an independent causative mechan-
ism [20, 30–33]. Thus, it is reasonable to search for the
more common prothrombotic states in patients with an-
other identified stroke risk factor and in patients with a
history of ischemic or thrombotic stroke (in this case, oral
contraceptives may be discontinued in adolescents). If
homocysteine is found to be elevated, aspecific diet or
supplementation with folate, vitamin B6, or vitamin B12
might be considered and, in general, patients who are
found to have a prothrombotic tendency should be re-
ferred to a haematologist [13, 34, 35].
Sickle cell disease
Children with SCD represent another important group
of patients with a high risk of arteriopathies and stroke.
Prior to modern primary prevention strategies, up to
11 % of children with SCD had a clinical stroke by the
age of 20 years. In 1992, transcranial Doppler (TCD)
was found to be effective in identifying SCD patients at
a high risk for stroke and currently primary prevention
is possible through chronic red blood cell transfusions in
SCD patients with elevated TCD velocity. This approach
has decreased the prevalence of overt stroke approxi-
mately to 1 % [13, 36–38].
Metabolic diseases
Metabolic infarctions are a rare but important condition
for the paediatric population. Energy depletion leads to
ischemic lesions in mitochondrial disorders. In urea
cycle disorders (especially OTCD), toxic deposits lead to
the destruction of cerebral tissue. For this reason, meta-
bolic infarctions do not occur in a specific vascularterritory (MELAS for example shows a predilection for
occipital infarctions). Other metabolic problems such as
Fabry disease lead to a focal arteriopathy [15, 39].
Congenital and acquired heart disease
Heart disease is still recognized as a presumed risk fac-
tor for paediatric stroke showing a high frequency in
case series (19 % of children with arterial thrombosis ac-
cording to the Canadian Paediatric Ischemic Stroke
Registry) [40]. Complex congenital heart lesions with
right-to-left shunting and cyanosis are particularly prone
to cause stroke (in particular if uncorrected or in the
peri-operative period), but stroke has also been de-
scribed in children with other cardiac congenital lesions
and occasionally with acquired disorders of the myocar-
dium or cardiac valves [12, 13, 34]. (For a summary of
paediatric stroke risk factors: see Table 1).
Diagnosis of paediatric stroke
Diagnosis of paediatric stroke is not simple and requires
a neuroimaging reference that at present is considered
essential to confirm the neurovascular origin of symp-
toms. Many cases receive delayed or post-mortem diag-
nosis, given the complexity of the presentation and the
potential ambiguity of the clinical findings. A median
time of 25 h between the onset of symptoms and the
radiological evidence of stroke has been observed and
only one third of the affected children are diagnosed
within a delay of six hours [41–43].
Signs and symptoms
Clinical presentation of paediatric stroke is variable de-
pending on the patient’s age and the involved artery.
We have already explained above that perinatal stroke
usually presents with more subtle and aspecific signs;
more generally, in younger children, stroke symptoms
are usually aspecific (seizures and altered mental status
may be the only manifestation of clinical stroke, in par-
ticular if age < 1 year) while in older children they become
more specific, often presenting with focal neurological
deficits such as hemiplegia.
In Table 2 we have summarized the clinical presentation
of paediatric stroke according to the involved cerebral ter-
ritory. In general, the presence of hemiparesis, disphasia/
aphasia (not limited to stroke of the dominant side in
childhood, because of immature lateralization of lan-
guage), and hemianopsia suggests a suvratentorial cerebral
territory involvement, while ataxia is a typical symptom of
an infratentorial stroke, but not limited to cerebellar le-
sions [44]. Headaches are present in 30 % of children and
considerable differential diagnosis are hemiplegic migraine
or dissection of carotid or vertebral artery [20].
Seizures have been described in 20–48 % of cases and
may be part of paediatric stroke clinical presentation in
Table 1 Risk factors for pediatric AIS
Artheriopathies Arterial fibromuscular dysplasia, arteriovenous malformation, arterial dissection, Moyamoya disease, transient
cerebral arteriopathy of childhood, primary central nervous system vasculitis, cranial radiotherapy
Vasculitis Meningitis, postinfectious systemic lupus erythematosus, polyarteritis nodosa, granulomatous angiitis, Takayasu’s




Hemoglobinopathies (sickle cell anemia, sickle cell-hemoglobin C, sickle-thalassemia), purpura, thrombocytosis,
polycythemia, disseminated intravascular coagulation, leukemia or other neoplasms, congenital coagulation
defects, oral contraceptive use, liver dysfunction with coagulation defect, vitamin K deficiency, Lupus
anticoagulant, anticardiolipin antibodies
Metabolic disorders Mitochondrial disorders (MELAS syndrome), urea matabolic disorders, homocystinuria, aminoaciduria, glutaric
acidemia type I, lysosomal disorders, Fabry’s disease
Heart diseases Congenital malformations (ventricular/atrial septal defect, patent ductus arteriosus, aortic/mitral stenosis,
coarctation, complex congenital heart defects);
Acquired (Rheumatic heart disease, endocarditis, myocarditis, arrhythmia)
Traumatic Child abuse, post-traumatic arterial dissection, blunt cervical arterial trauma, arteriography, post-traumatic carotid
cavernous fistula, penetrating intracranial trauma
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they occur in the first 24 h of stroke onset, a higher risk
for developing of Epilepsy in the next 6 months has been
observed [45].
Clinical history and physical examination
When collecting the clinical history, the physician should
consider risk factors for paediatric stroke (Table 1), inves-
tigating ethnic origin, familial history and in particular a
positive family history for coagulopathies, and cerebrovas-
cular, metabolic or immunologic diseases. Particular atten-
tion should be given in the personal history to the
presence of sickle cell disease or congenital heart disease,
to a history of head or neck trauma, to unexplained fever
and recent infections (especially chickenpox), vasculitis,
drug ingestion and blood disorders.
A complete physical and neurological examination
should be performed, considering the potential corres-
pondence between neurological deficit and specific brain
territory involved (Table 2). Signs of systemic diseases or
cardiovascular diseases that increase the risk of stroke
and skin lesions indicating trauma or infections should
be looked for.Table 2 Clinical presentation of stroke depending on the
involved artery
Vascular territory Symptoms
Internal carotid artery Hemiparesis, hemianopsia, aphasia
Anterior cerebral artery Hemiparesis (legs+++)
Middle cerebral artery Hemiparesis (arms+++), hemianopsia, aphasia
Posterior cerebral artery Hemiparesis, hemianopsia, ataxia
Basilar artery Sensory disturbance, nystagmus, ataxia, breath
alterations
Cerebellar artery Sensory disturbance, nystagmus, ataxia, tremor,
dysarthria, vertigo, vomitingNeuroimaging
In front of a child with acute neurological alterations with
the prevision of a thrombolytic or neurovascular interven-
tion, Magnetic Resonance Imaging (MRI) or non-contrast
Computer Tomography (CT) should be performed.
In particular, non-contrast CT is easily available in
emergency and can adequately exclude haemorrhagic
stroke (a contraindication to thrombolytic therapy) or a
mass effect produced by parenchymal abnormalities, fur-
thermore it may identify cerebral venous sinus throm-
bosis and low-density lesions in arterial ischemic stroke
(for example, hypoattenuation of the lentiform nucleus
in acute ischemia of the lenticulostriate territory or insu-
lar ribbon sign in cytotoxic edema of the insular cortex).
However, CT is usually normal within the first 12 h after
the onset of symptoms [46, 47].
MRI with diffusion-weighted imaging remains the
“gold standard” for the investigation of arterial ischemic
stroke in infants and children, due to its greater sensitiv-
ity and specificity [47, 48], but it is rarely available in the
the hyperacute phase managed in emergency depart-
ments. Typical MRI findings in patients with acute cere-
bral ischemia include hyperintense signal in white
matter on T2- weighted images and fluid-attenuated in-
version recovery images, with a resultant loss of grey
matter–white matter differentiation. Other findings may
be sulcal effacement and mass effect, loss of the arterial
flow voids and stasis of contrast material within vessels
in the affected territories [49–51] (Fig. 1). Otherwise, in
paediatric patients < 2 years, the incomplete myelinisa-
tion compromises the efficacy of fluid-attenuated inver-
sion recovery MRI sequences [52]. In patients with SCD
or other predisposing diseases, MR images may be char-
acterised by a coexistence/overlapping of the acute cere-
brovascular injury and chronic sequelae of previous
AISs. The diagnostic efficiency of MRI can be further
AB
Fig. 1 a Bilateral ischemic lesion of the ponto-mesencephalic junction, enhanced on the left side (day 1), 3d FLAIR, sagittal section. b Bilateral
ischemic lesion of the ponto-mesencephalic junction, enhanced on the left side (day 1), axial section
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tween infarct core and penumbra and by Susceptibility-
Weighted Imaging to estimate infarct progression [53, 54].
Magnetic Resonance Angiography allows the identifica-
tion of the involved vascular territory, and can be useful to
evaluate the effectiveness of thrombectomy (Figs. 2 and 3).
Vascular imaging of the carotid and vertebral arteries by
duplex ultrasonography, CT angiography (CTA), MRA or
catheter angiography should be considered within 24 h of
the stroke [55, 56].
Neuroimaging in Moyamoya disease
Conventional angiography or MRA are required to iden-
tify Moyamoya disease [34, 57]. In particular, MRI-MRA
may be sufficient to diagnose MMD when they find the
typical pattern of stenosis or occlusion of the terminal part
of the internal carotid artery and/or the proximal portion
of the ACA and/or MCA, the abnormal arterial vascular
network near the steno-occlusive lesions with the appear-
ance of a “puff of smoke” or two or more flow voids in the
basal ganglia, the sparing of posterior circulation. The
diagnosis is “definite MMD” if these findings are bilateraland is “probable MMD” if they are unilateral. The “Ivy
sign” may also be found from FLAIR sequences, consist-
ing in linear hypersignals that follow a sulcal pattern and
indicating a slowed cortical blood flow [58, 59].
Cerebral conventional angiography remains the gold
standard for diagnosis and classification of MMD and is
more reliable when applied to smaller vessel occlusions;
however, because of its invasivity, conventional angiog-
raphy is realized in limited circumstances, such as uncer-
tain diagnosis or progression of the angiopathy during
follow-up, pre-surgical management, evaluation after
surgical revascularization. The Suzuky classification, based
on the physiological reorganization process called
“internal carotid -external carotid conversion”, remains
the reference standard for evaluating disease severity [60].
The progressive bilateralization and the decrease of global
cerebral blood flow with a predominant posterior distribu-
tion are more frequent in pediatric patients with MMD
than in adult patients. Assessment of cerebral perfusion in
MMD may be obtained through cerebral hemodynamic
techniques (single photon emission computed tomog-
raphy [SPECT], perfusion CT, xenon-enhanced CT
AB
Fig. 2 a Thrombosis of the superior portion of the basilar trunk, acute phase (day 0), 3 DI Willis, sagittal section. b Thrombosis of the superior
portion of the basilar trunk, acute phase (day 0), 3 DI Willis, axial section
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arterial spin labeling) and metabolic techniques (positron
emission tomography [PET]-scan) [61–63].
Optional investigations
Laboratory examinations in the acute setting, including
routine chemistry, electrolytes, hematology and coagula-
tion should be conducted as part of the initial evaluation
[55]. Other investigations can be useful for differential
diagnosis with meningo-encephalitis (generally associated
with fever, headache and altered consciousness), metabolic
disorders, epilepsy (acute hemiplegia may be a sign of post-
seizure Todd-Palsy), idiopathic intracranial hypertension,
empyema and intracranial abscess, acute disseminated leu-
koencephalitis, cerebellitis, tumor, etc. (Table 3: Differential
diagnosis of paediatric stroke) and could be evaluated de-
pending on the specific clinical condition [64].
After-diagnosis investigations
Several studies may be helpful after the diagnosis of
paediatric stroke for the on-going evaluation and man-
agement of the patient.Electrocardiogram and transthoracic or transesopha-
geal echocardiogram are mandatory for a cardiological
work-up both in patients with known congenital heart
malformations or with suspicion of cardiac disease and
in patients with stroke of undetermined aetiology. Ac-
cording to the Royal College of Physicians Guidelines
(RCP; 2004), transthoracic cardiac echocardiography
should be undertaken within 48 h of presentation with
AIS [35].
Haemoglobin electrophoresis may be indicated to
identify hemoglobinopathies which represents a risk fac-
tor for stroke (SCD, sickle cell-hemoglobin C, sickle-
thalassemia).
A full evaluation for thrombophilia is reasonable in all
children with stroke and may include protein C and pro-
tein S deficiency, antithrombin III, heparin cofactor II,
plasminogen, vonWillebrand antigen, factor VIII, factor
XII, factor V Leiden, activated protein C resistance, pro-
thrombin 20210 gene, serum homocysteine, MTHFR,
lipoprotein (a), and antiphospholipid antibodies.
Screening for metabolic, immunologic disorders and
infections related to stroke (in particular, VZV,
AB
Fig. 3 a After thrombectomy of the basilar trunk (day 1), 3DI Willis, sagittal section (before thrombectomy: see Fig. 2a). b After thrombectomy of
the basilar trunk (day 1), 3DI Willis, axial section (before thrombectomy: see Fig. 2b)
Table 3 Differential diagnosis of ischemic stroke
Hemorrhagic stroke
Cerebral venous sinus thrombosis
Hemiplegic migraine
Todd’s Palsy
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infective endocarditis) and research of drug intoxication
(especially sympathomimetics) could be evaluated de-
pending on the specific clinical condition [34, 65, 66].
Treatment of pediatric stroke
The main target of treatment of paediatric stroke is the
protection of the developing brain by minimizing acute
brain injury, preventing neurodevelopmental impairment
and disability.
Because of the lack of data from paediatric studies,
there is no evidence-based treatment for paediatric
stroke. Nevertheless recent guidelines such as the
Canadian Best Practice Guidelines (CBP; 2010), the
American College of Chest Physicians Evidence-Based
Clinical Practice Guidelines (CHEST; 2012), the
American Heart Association Guidelines (AHA; 2008)
and the RCP 2004, that extrapolate data both from
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clinician [35, 55, 67].
Firstly, children with acute stroke may be hospitalized
in a clinical unit with the possibility of continuous moni-
toring. In selected cases transfer to intensive care units
is needed [68, 69].
Acute phase treatment
In general, guidelines consistently recommend anti-
thrombotic treatment for paediatric AIS; before start-
ing the treatment, exclusion of haemorrhagic stroke is
mandatory.
The specific indications of anticoagulant therapy remain
controversial. Most guidelines recommend treatment with
Unfractioned heparin (UFH) or low molecular-weight hep-
arin (LMWH) in children with a proven arterial dissection
or cardioembolic stroke or during the diagnostic evalu-
ation period, until cardioembolism or an arterial dissec-
tion have been excluded. Nevertheless, the RCP
recommends initial treatment of childhood AIS with as-
pirin 5 mg/kg until an indication for anticoagulation is
found and, according to CBP 2010, the use of anticoagula-
tion in children with cardiac embolism stays controversial
and the risk of haemorrhagic transformation of the infarct
must be considered and individualised with the help of
paediatric cardiologists and neurologists.
Heparin may be considered taking into account a risk/
benefit balance because of the reported heparin-induced
thrombocytopenia and thrombotic complications. Ac-
cording to guidelines, LMWH can be started safely in
paediatric AIS at a dose of 1 mg/kg twice a day.
Heparin-based anticoagulation, when employed, is best
monitored with anti-factor Xa activity considering as a
therapeutic range 0.35 to 0.7 anti-factor Xa activity
U/mL for unfractionated heparin and 0.5 to1.0 U/mL
for LMWH in a sample taken 4 to 6 h after subcuta-
neous injection.
Pharmacological and mechanical thrombolysis
Guidelines do not recommend the use of both thromb-
olysis by tissue plasminogen activator (t-PA, Alteplase)
and mechanical thrombectomy in children outside spe-
cific research protocols.
Despite the lack of evidence of safety and efficacy in
paediatric patients, these techniques have been applied
to children with AIS based on evidence from a few case
reports and case series, as well as extrapolation from the
adult literature. In particular, 34 published cases of
paediatric endovascular treatment including intra-
arterial alteplase were reviewed in 2011 and about 2 %
of children in the US with AIS are treated with intraven-
ous thrombolysis [70–72].
Adult AIS patients are now routinely given systemic
tPA when presenting within 3 h from stroke onset, at ausual dose of 0.9 (max 90 mg) mg/kg, with a 10 % of the
dose as a bolus and the remaining as a 1-h infusion [73].
Concerning paediatric stroke population, a study was
started to define intravenous alteplase safety and dose-
finding within 4–5 h from stroke onset, but it was halted
because of insufficient recruitment [74, 75].
Intra-arterial thrombolysis, which extends the window
of treatment by endovascular approaches from 3 to 6 h,,
is successfully utilized in the adult population. In paedi-
atric patients no randomised controlled trials are avail-
able but small cohorts underwent the procedure with
encouraging results, excepted for one patient who died
for MCA occlusion, while suffering from carotid bifur-
cation occlusion (which is known to present a poor
prognosis in adults).
Endovascular mechanical thrombectomy has also been
used in children despite, as already explained, guidelines
advise against its exportation in the paediatric popula-
tion. The potential candidates for this approach may
be paediatric patients with a large intracranial artery
occlusion. Safety guidelines are needed considering
the risks associated with the treatment of children as
small adults and the inappropriateness of devices
often designed for adult use. Concerning decision
making, the entity of the neurological deficits, the di-
mension of the involved artery, the MRI evidence of
preservation of brain tissue and the familiarity of the
centre with paediatric stroke treatments, may be con-
sidered [71, 76].
Secondary prevention
Even in the absence of randomized clinical trials for the
acute treatment of AIS in children, most experts agree
that aspirin use is reasonable for secondary stroke pre-
vention in children that are not at high risk of recurrent
embolism and that are not affected by a hypercoaguable
disorder. The dose varies from 1–5 mg/kg/die following
the principal guidelines (a dose of 3 to 5 mg/kg per day
is reasonable considering a reduction to 1 to 3 mg/kg in
the case of dose-related side effects, CHEST 2012). The
optimum duration of aspirin therapy is poorly defined,
although a minimum of 2 years of therapy is suggested.
The increased risk of Reye’s syndrome should be consid-
ered. If children are unable to take aspirin, clopidogrel
may be considered as an alternative treatment at dosages
of about 1 mg/kg per day, while the combination of clo-
pidogrel and aspirin should be used with caution [77].
LMWH or warfarin are recommended in secondary
prophylaxis by the RCP guidelines in children with car-
dioembolism or extracranial arterial dissection and may
be considered in children with cerebral venous sinus
thrombosis according to CBP 2010 and in children with
recurrent AIS despite aspirin treatment according to
CHEST 2012 and CBP 2010. The AHA guidelines also
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phospholipid antibody syndrome.
Surgical intervention may be considered for AIS
secondary to cardioembolic causes in the case of
demonstrated right-to-left shunts (eg, patent foramen
ovale) [67].
Some institutions have recently successfully developed
a paediatric service for anticoagulation safety [78] and a
large recent nonrandomized study found no difference
in secondary stroke prevention with the use of warfarin
versus aspirin after cervical artery dissection [79].
In conclusion, the comparison between antiplatelet
and anticoagulant drugs for safety and efficacy remains
controversial. Although preliminary studies suggest that
anticoagulation may be safe in children with AIS (even
in those with arteriopathy), the need of a randomised
clinical trial to establish the optimum antithrombotic
treatment of paediatric stroke and its secondary preven-
tion persists.
Treatment in particular conditions
In SCD primary management consists of evaluation by a
multi-disciplinary team (a hematologist, neurologist,
neuroradiologist and a transfusion medicine specialist);
prompt neuro-imaging, and an initial simple blood
transfusion followed immediately by an exchange trans-
fusion or only exchange transfusion (with the aim of ex-
changing hemoglobin A with sickle cells hemoglobin
without increasing cerebral blood volume) if the
hemoglobin is > 4 gm/dL and < 10 gm/dL. Standard ther-
apy for secondary prevention of stroke and silent cere-
bral infarcts includes regular blood transfusion therapy
and in selected cases, hematopoietic stem cell trans-
plantation [37, 38, 76].
In metabolic diseases, the first-line therapy is correc-
tion of the underlying metabolic defect. In Moyamoya,
therapy is mainly surgical revascularization to establish
an alternative source of vascular flow for hypoperfused
territories. The existence of different patterns of Moya-
moya disease and the rarity of this condition, solicit an
individualized decision making and the patient should
be referred for evaluation to a centre with expertise in
evaluating patients for surgical revascularisation [34].
Despite a vast literature about Moyamoya, the need of
controlled clinical trials to guide the decision of therapy
persists [24, 80, 81].
Supportive care
Patients should receive supportive care with particular
attention to optimisation of glycaemia, volemia, oxygen-
ation and blood pressure and to prevent and correct
hyperthermia and infections [34, 82]. Management of
physiologic clinical and laboratory status may follow the
general statements for the acutely ill child [83].To prevent secondary brain injury, seizures may be
controlled (with eventual continuous electroencephalo-
graphic monitoring and antiepileptic medications in the
case of clinical or electrographic seizures) and a normal
oxygenation may be assured. No benefits have been ob-
served with oxygen supplementation in the absence of
hypoxemia neither with the use of hypothermia in paedi-
atric stroke [34, 84, 85].
Concerning blood pressure control, management of
elevated blood pressure in paediatric patients with
AIS remains controversial due to the lack of evidence
for a particular pressure range target. In general, ex-
treme blood pressure elevation (e.g. systolic > 220 or
diastolic > 120 mmHg) may be treated to reduce the blood
pressure by ~15 %, and not more than 25 %, over the first
24 h with a gradual reduction thereafter. Excessive lower-
ing of blood pressure should be avoided as this may ex-
acerbate or may induce ischemia [57, 72].
Artificial hyperventilation and osmotic agents may be
considered in children with intracranial hypertension.
In the case of necessary hydrocephalus drainage or de-
compressive craniectomy for massive cerebellar infarc-
tion, transfer to a neurosurgery department must be
evaluated.
Rehabilitation
Given the plasticity of the young brain, rehabilitation for
children following stroke can likely lead to vast improve-
ments in long-term outcomes, with a favourable impact
in long-term morbidity, quality of life and emotional
health for the child and the family [86]. A multidisciplin-
ary team should be involved in paediatric stroke rehabili-
tation utilizing a biopsychosocial model and taking into
account that the emotional well-being of the family
following a stroke may influence the recovery of the
child [57, 73]. Adjunctive therapies have shown encour-
aging results in animal models and are now being stud-
ied in both adults and children with stroke, including
constraint-induced movement therapy (CIMT), bi-
manual training and transcranial magnetic stimulation.
These techniques have been defined as relatively safe,
with a maximum benefit when performed in crucial pe-
riods of early development and with hopeful improve-
ments in motor long-term follow-up [87–99].
Conclusions
Paediatric stroke is a relatively rare disease associated to
a significant morbidity and mortality so to deserve the
attention of clinicians. Stroke may have a subtle presen-
tation in particular among new-borns and in younger
children, but in general it should be taken into account
in the differential diagnosis of any child presenting with
new-onset focal deficits, altered speech, ataxia, import-
ant headache, seizures or alterations of mental state.
Rosa et al. Italian Journal of Pediatrics  (2015) 41:95 Page 10 of 12Advanced imaging devices have improved the diagnosis
of paediatric stroke; MRI techniques are considered the
“gold standard” and different combinations of radio-
logical exams may be applied according to current
guidelines and to the specific clinical condition. Al-
though recently published guidelines, often extrapolating
data from an adult population, may help the clinician in
paediatric stroke treatment decisions, controlled rando-
mised studies to determine the optimal acute treatment
of paediatric stroke and its secondary optimal prevention
and rehabilitation are critically needed.
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